Cary Street Partners Investment Advisory’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
Other funds holding XBI
MIH
MSR
PR
IL
Cary Street Partners Investment Advisory's XBI Position: Q2 2026 in Review
Cary Street Partners Investment Advisory reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 57% in Q2 2026, selling an estimated $33.1K and leaving 185 shares worth $29.3K. The position accounts for 0.01% of the portfolio, ranked #632.
Cary Street Partners Investment Advisory first reported a position in XBI in Q3 2020 and has held it in 14 quarters since. The position peaked at $574K in Q1 2024. 648 funds tracked by Wall St. Rank hold XBI as of Q2 2026.
- Cary Street Partners Investment Advisory held 185 shares of State Street SPDR S&P Biotech ETF worth $29.3K as of Q2 2026.
- Cary Street Partners Investment Advisory sold 245 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $33.1K.
- State Street SPDR S&P Biotech ETF made up 0.01% of Cary Street Partners Investment Advisory's portfolio in Q2 2026, its #632 holding.
- Cary Street Partners Investment Advisory first reported a position in State Street SPDR S&P Biotech ETF in Q3 2020 and has held it in 14 quarters since.
- Cary Street Partners Investment Advisory's State Street SPDR S&P Biotech ETF position peaked at $574K in Q1 2024.
- 648 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.
Based on Cary Street Partners Investment Advisory's 13F filing for Q2 2026, filed 17 Jul 2026.